Midi Health Review: What Its GLP-1 Documentation Establishes—and What It Doesn’t

A weight-management service can document how patients book appointments without demonstrating how well its particular treatments work. Midi Health illustrates that distinction. Its public materials describe virtual care for women, an initial assessment, follow-up visits, brand-name GLP-1 prescriptions and compounded GLP-1 or GLP-1/GIP options. Those are meaningful service details, but they are not clinical trial results. For someone comparing providers, the central question is which claims describe an operational offering and which require evidence about a specific medicine, formulation or route.

This review examines Midi’s public documentation consulted October 19, 2026. The strongest details concern visit length, self-pay charges, separate medication billing and the division between platform, medical groups and pharmacies. Less settled are the exact ingredients in each advertised compound, formulation-specific state availability and conflicting Medicare statements. The approach follows a basic rule of reading provider documentation: a published service description establishes what a company represents, not independent verification of credentials, treatment quality or patient outcomes.

At a glance

Documented treatment options: Midi advertises brand-name GLP-1 prescriptions and compounded GLP-1 and GLP-1/GIP prescriptions; compounded options include self-injection and sublingual drops.
Sources: [7] [10]
Visit charges: Self-pay pricing is $250 for a 30-minute first visit and $150 for a 15-minute returning visit. Medication is separate.
Sources: [8] [7]
Compounded medication starting price: Compounded GLP-1 and GLP-1/GIP medication starts at $164 per four-week supply, depending on medication, format and dose, including shipping and supplies.
Sources: [7]
Regulatory distinction: Midi discloses that compounded medicines are not FDA approved. FDA recommends compounding when an individual’s medical needs cannot be met by an approved drug.
Sources: [11] [1]
Unresolved access differences: General advertising says all 50 states, while GLP-1-specific material says not all 50. Public pages also disagree about Medicare beneficiaries using self-pay.
Sources: [7] [9] [8] [6]

Start with the product, not the GLP-1 label

Midi’s weight-management offering is not one standardized product. It advertises compounded GLP-1 and GLP-1/GIP prescriptions, plus brand-name GLP-1 prescriptions sent to a patient’s pharmacy of choice. Its compounded GLP-1 page describes self-injection and oral drops, with the latter placed under the tongue. That makes the drops sublingual preparations, not swallowed tablets. The consulted documentation does not unambiguously identify the active ingredient in every preparation marketed under these broad categories. Educational references to familiar drug names do not resolve that product-level gap.

These distinctions matter before interpreting any effectiveness claim. Evidence about one product or delivery route cannot simply be attached to another because both carry a GLP-1 label. Our guide to formulation and route explains that evidence question. Midi says a clinician evaluates medical history and symptoms to decide what is appropriate, and its terms require a completed consultation, a favorable prescribing decision and a valid prescription. The advertised selection therefore represents possible offerings, not a guaranteed prescription or an assurance that every format is available to every patient.

Sources: [10] [7] [14] [3] [4]

What clinical evidence can—and cannot—say about Midi

Midi explicitly states that its compounded medications are not FDA approved and do not undergo FDA review for safety, effectiveness or quality before becoming available. FDA approval concerns a specific product; it is not an approval of a clinic or pharmacy. FDA recommends compounded drugs for patients whose medical needs cannot be met by an FDA-approved drug, with a prescription and a state-licensed pharmacy. Nonapproval alone does not establish clinical inequivalence, but it also does not supply evidence of equivalence. These are separate questions, as our approved-versus-compounded evidence guide explains.

The clinical studies in this review’s context are trials of particular subcutaneous semaglutide and tirzepatide regimens, not studies of Midi. They do not establish outcomes for its compounded preparations, sublingual drops or advertised “microdosing” programs. Midi says those programs are built around individual needs when clinically appropriate; that is a service claim, not trial validation. No provider-specific outcome study is established by the consulted documentation. The useful distinction is between evidence supporting a studied medicine and evidence showing results from this particular service—a distinction explored in trials versus provider performance.

Sources: [11] [7] [1] [3] [4]

Who actually provides the care

Midi describes itself commercially as a virtual healthcare clinic for women and says all its clinicians are board-certified and trained in women’s health. Those are provider statements, not independently verified credentials in this review. Its legal terms make a separate organizational distinction: Midi Health, Inc. and its subsidiaries operate the platform, while Midi itself is not the healthcare provider. Using the platform alone does not create a clinician-patient relationship with Midi. That distinction helps identify whose responsibilities a patient should clarify when arranging treatment or resolving a clinical concern.

The terms identify four medical groups: Integrative Women’s Care PC, IWC Medical Group, P.A., IWC Medical Group KS, P.A., and Robert G. Aptekar, M.D., P.C. They employ or contract with physicians, nurses, allied health professionals and other health professionals. A Midi clinician therefore should not automatically be described as a physician. General access requires being at least 18, or the local age of majority if higher, and being located in a state served by the platform. These access conditions do not establish medication eligibility, and the consulted materials do not provide complete exclusion criteria.

Sources: [13] [14]

The documented assessment and follow-up process

Before the appointment, Midi asks patients to complete a questionnaire covering health and weight history, current medicines, previous treatments, risk factors and goals. The first virtual visit lasts about 30 minutes and reviews history, symptoms, past treatment and goals before producing a personalized care plan and follow-up recommendations. The program also describes targeted laboratory testing, such as blood sugar or cholesterol, to inform metabolic care. These details establish a proposed assessment process. They do not establish a uniform laboratory requirement, a specific eligibility threshold or a guaranteed timetable for completing the assessment.

A care plan may include GLP-1 medication, laboratory orders and guidance. Midi advertises 15-minute follow-up visits to track progress and adjust care, and says its clinicians help manage side effects. A separate article says patients prescribed personalized GLP-1 medicines also receive ondansetron tablets for nausea and vomiting; it does not specify universal inclusion or pricing. Follow-up is clinically relevant because treatment decisions involve response and tolerability, not merely continued payment. Still, the public descriptions do not establish continuous clinical availability, a standard follow-up frequency or a guaranteed response time between appointments.

Sources: [7] [10] [12] [2]

The prices are concrete, but not an all-in treatment quote

Midi advertises no membership fees: patients pay for care and medication. Its published self-pay charges are $250 for the 30-minute initial visit and $150 for a 15-minute returning visit. Medication is explicitly priced separately. The compounded medication offer starts at $164 per four-week supply, depending on medication, format and dose, including shipping and supplies. Four weeks is not a calendar month, and a starting price does not establish the price of every formulation. The public materials do not assemble visits, medicines and laboratories into a single treatment-period total.

The separate “microdosing” offer starts at $34 per weekly dose for eligible patients when clinically appropriate. It is not an all-inclusive weekly care price, and the consulted evidence does not define every eligible presentation. Brand-name prescription costs depend on the drug and insurance, with fulfillment through the chosen pharmacy. Midi also says HSA or FSA funds can pay for its visits and services. These are useful billing details, but none establishes a medication price lock, a uniform renewal charge or a guaranteed amount of insurance reimbursement.

Published charges and their boundaries
Item	Published price	Important boundary
Initial self-pay visit	$250 for 30 minutes	Medication is priced separately
Returning self-pay visit	$150 for 15 minutes	Not a monthly membership charge
Compounded GLP-1 or GLP-1/GIP	Starts at $164 per four-week supply	Varies by medication, format and dose; includes shipping and supplies
Advertised microdosing option	Weekly doses start at $34	Eligible patients only, if clinically appropriate; not total care cost
Brand-name GLP-1 prescription	Depends on insurance and drug cost	Sent to the patient’s pharmacy of choice

Sources: [8] [11] [7]

Coverage and geography need product-specific confirmation

Midi’s program page advertises availability in all 50 states, but GLP-1-specific material says the offering is not available in all 50. These statements may concern different scopes of service; neither supplies a state-by-formulation list that resolves the difference. Patients should therefore confirm the exact medication and route available where they will receive care. Insurance language also needs precision. Midi says it is in-network with most major insurers, but deductibles, coinsurance and copays may apply. During registration, it requests an insurance-card photo to check network status and offers self-pay booking when out of network.

Medicare presents a clearer documentary conflict. The pricing page welcomes Medicare beneficiaries as self-pay patients while stating that they cannot submit claims related to Midi visits, medications or associated services. An article updated in December 2024 instead says Medicare, Medicaid and Medi-Cal patients cannot be treated even as self-pay patients. Both sources exclude Medicaid and Medi-Cal patients. The documentation does not resolve which Medicare statement governs a particular booking. Separately, insurance acceptance for a visit does not establish coverage for weight-management medication; that requires confirmation with the plan.

Sources: [7] [9] [8] [6] [2]

Pharmacy and delivery claims have defined limits

The terms specifically identify Precision Compounding Pharmacy as a prescription-fulfillment pharmacy. Other public material describes partner compounding pharmacies as licensed and “503A-accredited”; this review does not independently verify those representations. The terms also allow certain prescriptions to be sent to another pharmacy, in which case the patient pays that pharmacy directly and arranges pickup or other receipt. That language does not prove that every custom preparation can be filled through every outside pharmacy. Brand-name prescriptions are expressly advertised as going to the patient’s pharmacy of choice.

Midi says the starting compounded price includes shipping and supplies and that orders ship discreetly. Its store terms require a physical U.S. address and treat delivery dates as estimates, not guarantees. The consulted materials do not establish a guaranteed dispatch date, arrival date or formulation-specific cold-chain process. FDA advises not using an injectable GLP-1 product that arrives warm or inadequately refrigerated and contacting the provider or dispensing pharmacy. The terms also warn that not all pharmacy-filled prescriptions use child-resistant packaging. Neither discreet shipping nor included shipping establishes those additional protections.

Sources: [14] [11] [7] [1]

Renewal terms and retail products should not be confused with care

No membership fee does not mean no recurring product billing. The terms allow certain supplements and prescription products called CustomRx to renew automatically until canceled. They require cancellation before the deadline in the applicable subscription terms and ordinarily exclude refunds for partially used periods, subject to stated exceptions. Cancellation is available through the account, support@joinmidi.com or 1-888-731-8994. The first renewal may be charged early; later shipments may be charged and dispatched up to two days early. These general provisions do not establish that every GLP-1 prescription uses a subscription.

CustomRx billing and shipment require an active, refill-eligible prescription, product eligibility, pharmacy ability to dispense and legal availability in the patient’s state. Separately, Midi sells Daily GLP-1 Support, described as a nutritional supplement rather than a weight-loss product or a way to change GLP-1 efficacy. Its listing inconsistently displays 20% and 10% subscription discounts. Published store and accessibility support hours are weekdays, 9 a.m.–5 p.m. Eastern, with store@joinmidi.com and the same phone number; these are not continuous clinical-support hours. The consulted terms excerpt also omits a central section, limiting conclusions about the complete agreement.

Sources: [14] [5]

Questions & answers

Does Midi guarantee a GLP-1 prescription after the first visit?

No. Midi’s terms require a consultation, a clinician’s determination that the prescription product is appropriate and a written prescription. Its care plan may include GLP-1 treatment, laboratory orders and guidance, but the appointment itself does not guarantee medication. The consulted documentation also does not provide complete clinical exclusion criteria or uniform laboratory requirements. Ask what information the clinician needs before booking rather than interpreting the medication menu as a promise of access.

Sources: [14] [7]

Is the $164 offer the total cost of starting Midi?

No. It is a starting price for a four-week supply of compounded GLP-1 or GLP-1/GIP medication, varying by medication, format and dose, with shipping and supplies included. Visits are separate: the initial self-pay appointment is $250 and returning visits are $150. The public documentation does not establish an all-in package covering laboratory work and a defined course of follow-up. Request an itemized quote for the proposed treatment rather than treating the advertised medication minimum as the entire bill.

Sources: [7] [8]

Are Midi’s oral drops the same as an approved oral tablet?

The documented drops are placed under the tongue, so they should not be described as swallowed tablets. The consulted materials do not establish that they share a tablet’s formulation, approval or clinical results. Midi discloses that its compounded medicines are not FDA approved. Ask for the exact active ingredient, formulation and supporting evidence for the proposed route. Evidence from a different product is not automatically evidence for these drops.

Sources: [10] [11] [1] [3]

Can a Medicare beneficiary book a self-pay Midi visit?

The public pages conflict. The pricing page says Medicare beneficiaries may use self-pay but cannot submit related claims for visits, medications or associated services. A separate article says Midi cannot treat Medicare patients even as self-pay patients. Confirm the currently applicable policy directly before booking, ideally with a written response. Both consulted statements exclude Medicaid and Medi-Cal patients; the self-pay option should not be assumed to override those restrictions.

Sources: [8] [6]

Can I use my own pharmacy for a Midi prescription?

Midi expressly says brand-name GLP-1 prescriptions go to the pharmacy of your choice. Its terms also describe sending certain prescriptions to an outside pharmacy, with the patient responsible for paying that pharmacy and obtaining the product. This does not confirm unrestricted transferability of every compounded preparation. Before selecting a pharmacy, clarify which product is being prescribed, whether that pharmacy can dispense it and who handles delivery, supplies and prescription-related questions.

Sources: [7] [14]

Does canceling a Midi product subscription produce a refund?

Not ordinarily for a partially used subscription period. The terms distinguish stopping future recurring charges from refunding a period already underway, with discretionary or legally required exceptions. They permit cancellation through the account, email or telephone, but the applicable subscription deadline governs avoiding the next charge. Because some charges and shipments may occur early, confirm the actual billing schedule. These product-subscription rules do not establish the policy for late appointment cancellation or missed visits.

Sources: [14]

Our assessment

Midi documents a recognizable care pathway rather than merely a medication checkout: a history questionnaire, a substantial first visit, potential laboratory testing and shorter follow-up appointments. It also publishes useful self-pay visit prices and clearly separates medication charges. The evidence boundary is equally important. Those operational details do not establish outcomes for its compounded injections, sublingual drops or microdosing programs, and the consulted materials leave exact formulation details unresolved. State-specific GLP-1 access and Medicare eligibility also need direct confirmation. A productive next step is to request the precise product and route, prescribing medical group, dispensing pharmacy, itemized charges and applicable renewal terms. Midi offers enough documentation to support that conversation, but not enough to treat its broad product categories or promotional claims as formulation-specific clinical evidence.

Visit Midi Health’s official site ↗

This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

Midi Health Review: What Its GLP-1 Documentation Establishes—and What It Doesn’t

At a glance

01Start with the product, not the GLP-1 label

02What clinical evidence can—and cannot—say about Midi

03Who actually provides the care

04The documented assessment and follow-up process

05The prices are concrete, but not an all-in treatment quote

06Coverage and geography need product-specific confirmation

07Pharmacy and delivery claims have defined limits

08Renewal terms and retail products should not be confused with care